文献速递系统性红斑狼疮脊柱关节炎

Janus激酶抑制剂在体外增强人全血中前列腺素类生物合成:对心血管副作用及预防策略的意义

Janus kinase inhibitors enhance prostanoid biosynthesis in human whole blood in vitro: implications for cardiovascular side effects and prevention strategies.
PubMed 文献 · Ann Rheum Dis · 2025-05-05

本研究在体外评估4种Janus激酶抑制剂(托法替布、巴瑞替尼、非戈替尼、乌帕替尼)对健康人及系统性红斑狼疮、轴性脊柱关节炎患者全血中血栓素B2生成的影响,发现所有JAK抑制剂均增加凝血全血血清TXB2生成,托法替布和巴瑞替尼还增加脂多糖刺激后TXB2生成,阿司匹林几乎完全抑制该效应。

要点

  • 所有JAK抑制剂均增加凝血全血血清TXB2生成,但非浓度依赖性。
  • 托法替布(1 μM)显著增加健康人、SLE和axSpA患者LPS刺激全血TXB2生成。
  • 阿司匹林(100 μM)在JAK抑制剂存在下几乎完全降低血清TXB2。

核心结论

  • 血小板中TXA2生物合成增强(白细胞贡献较小)可能促进JAK抑制剂相关心血管风险升高。
  • 低剂量阿司匹林可能提供保护作用,需进一步研究。

研究设计与样本

  • 体外研究,评估4种JAK抑制剂(托法替布、巴瑞替尼、非戈替尼、乌帕替尼,0.04-20.0 μM)对健康受试者凝血全血TXB2生物合成的影响。
  • 评估上述JAK抑制剂对健康受试者、系统性红斑狼疮患者和治疗初治轴性脊柱关节炎患者全血经24小时脂多糖刺激后TXB2生成的影响。

主要发现

  • 所有JAK抑制剂均增加凝血全血血清TXB2生成,但非浓度依赖性。
  • 脂多糖刺激全血中,托法替布(1 μM)显著增加健康受试者TXB2生成(42% ± 33%,n = 17)。
  • 托法替布(1 μM)显著增加SLE患者TXB2生成(57% ± 39%,n = 12)和axSpA患者TXB2生成(31% ± 23%,n = 15)。
  • 巴瑞替尼(1 μM)增加健康受试者TXB2生成(30% ± 22%,n = 10)。
  • 乌帕替尼显示TXB2增加趋势(46% ± 40%,n = 7),非戈替尼未显示(21% ± 19%,n = 7)。

临床怎么用

  • 作者认为血小板中TXA2生物合成增强可能促进JAK抑制剂相关心血管风险升高。
  • 作者认为低剂量阿司匹林可能提供保护作用,需进一步研究。

局限性

  • 原文结论指出需进一步研究(warranting further investigations)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Janus kinase inhibitors (JAKis) effectively treat chronic inflammatory diseases but are associated with cardiovascular side effects through unknown mechanisms. This study aimed to investigate the impact of JAKis on prothrombotic thromboxane (TX)A2 production in human whole blood (WB) as a possible mechanism. METHODS: We evaluated the effects of 4 JAKis- tofacitinib, baricitinib, filgotinib, and upadacitinib (0.04-20.0 μM)-on TXB2 biosynthesis in clotting WB from healthy subjects, serving as a marker for platelet TXA2 generation. Additionally, we assessed the impact of these JAKis on TXB2 production in WB from healthy subjects, patients with systemic lupus erythematosus (SLE), and treatment-naïve patients with axial spondyloarthritis (axSpA) after 24-hour lipopolysaccharide (LPS) stimulation, as a marker of platelet and leukocyte prostanoid biosynthesis. RESULTS: All JAKis increased serum TXB2 production in clotting WB, although not in a concentration-dependent manner. In LPS-stimulated WB, tofacitinib (1 μM) significantly increased TXB2 production in healthy subjects (HSs) (42% ± 33%, n = 17), patients with SLE (57% ± 39%, n = 12), and patients with axSpA (31% ± 23%, n = 15). Baricitinib (1 μM) also increased TXB2 in HSs (30% ± 22%, n = 10). Upadacitinib showed a trend towards increased TXB2 (46% ± 40%, n = 7), while filgotinib did not (21% ± 19%, n = 7). Aspirin (100 μM) almost completely reduced serum TXB2 in the presence of all JAKis. CONCLUSIONS: The enhanced biosynthesis of TXA2 in platelets, with a minor contribution from leukocytes, may contribute to the increased cardiovascular risk associated with JAKis. Low-dose aspirin may offer a protective effect, warranting further investigations.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Alabbasi S, Tacconelli S, de Vries M, et al. Janus kinase inhibitors enhance prostanoid biosynthesis in human whole blood in vitro: implications for cardiovascular side effects and prevention strategies. Ann Rheum Dis. 2025. PMID: 40328613. doi:10.1016/j.ard.2025.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。